4 completed, 3 recruiting, 2 withdrawn, 1 not yet recruiting. 11 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 11 | Completed 4, Recruiting 3, Withdrawn 2, Not yet recruiting 1, Terminated 1 |
| Phase 2 | 5 | Completed 3, Not yet recruiting 1, Recruiting 1 |
Follow Post-polycythemia Vera Myelofibrosis: new trials by email Literature Review of Post-polycythemia Vera Myelofibrosis trials Research Report on Post-polycythemia Vera Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Revumenib in Patients With Myelofibrosis Revumenib, Ruxolitinib, FEDRATINIB - Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Not yet recruiting | John Mascarenhas | 32 | 2026-12-01 | 2026-07-29 |
| A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms PRT12396 - Polycythemia Vera (PV), Myelofibrosis (MF) | Phase 1 | Recruiting | Prelude Therapeutics Incorporated | 100 | 2026-04-29 | 2026-10-29 |
| Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) Ruxolitinib, Tasquinimod - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 33 | 2024-08-01 | 2026-05-26 |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition Talazoparib, pacritinib - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 1 | Recruiting | Fox Chase Cancer Center | 24 | 2024-04-05 | 2024-05-03 |
| A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia LNK01002 - Acute Myeloid Leukemia, Primary Myelofibrosis | Phase 1 | Withdrawn | Lynk Pharmaceuticals Co., Ltd | 2021-04-08 | 2023-06-18 | |
| INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders INCB000928, ruxolitinib - Anemia, Post-essential Thrombocythemia Myelofibrosis | Phase 1 / Phase 2 | Completed | Incyte Corporation | 84 | 2021-03-19 | 2026-10-01 |
| Study of Select Combinations in Adults With Myelofibrosis MBG453, NIS793, Spartalizumab - Primary Myelofibrosis, Myelofibrosis | Phase 1 | Withdrawn | Novartis Pharmaceuticals | 2020-11-30 | 2021-03-04 | |
| MPN-RC 118 AVID200 in Myelofibrosis AVID200 - Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis | Phase 1 | Completed | John Mascarenhas | 21 | 2019-02-15 | 2023-02-10 |
| Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis PU-H71, Ruxolitinib - Myelofibrosis, Primary Myelofibrosis | Phase 1 | Terminated | Samus Therapeutics, Inc. | 4 | 2018-05-24 | 2022-11-15 |
| Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF NS-018 - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Completed | NS Pharma, Inc. | 77 | 2011-06-01 | 2022-03-09 |
| Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET) CYT387 - Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis | Phase 1 / Phase 2 | Completed | Sierra Oncology LLC - a GSK company | 166 | 2009-11-01 | 2019-02-01 |
Primary Myelofibrosis (10) · Polycythemia Vera (5) · Myeloproliferative Disorders (4) · Thrombocythemia, Essential (3) · Anemia (1) · Bone Marrow Diseases (1) · Fibrosis (1) · Hematologic Diseases (1) · Leukemia, Myeloid, Acute (1) · Leukemia, Myelomonocytic, Chronic (1) · Splenomegaly (1)
Hemic and Lymphatic Diseases (11) · Hematologic Diseases (10) · Bone Marrow Diseases (9) · Myeloproliferative Disorders (6) · Bone Marrow Neoplasms (5) · Hematologic Neoplasms (5) · Neoplasms (5) · Neoplasms by Site (5) · Blood Coagulation Disorders (3) · Blood Platelet Disorders (3) · Hemorrhagic Disorders (3) · Thrombocytosis (3) · Leukemia (2) · Leukemia, Myeloid (2) · Neoplasms by Histologic Type (2)
ruxolitinib (4) · N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide (2) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · 9H-purine-9-propanamine, 6-amino-8-((6-iodo-1,3-benzodioxol-5-yl)thio)-N-(1-methylethyl)- (1) · Decitabine (1) · NIS-793 (1) · fedratinib (1) · revumenib (1) · sabatolimab (1) · spartalizumab (1) · talazoparib (1) · tasquinimod (1)
John Mascarenhas (2) · Fox Chase Cancer Center (1) · Incyte Corporation (1) · Lynk Pharmaceuticals Co., Ltd (1) · M.D. Anderson Cancer Center (1) · NS Pharma, Inc. (1) · Novartis Pharmaceuticals (1) · Prelude Therapeutics Incorporated (1) · Samus Therapeutics, Inc. (1) · Sierra Oncology LLC - a GSK company (1)
United States (10) · Australia (2) · Canada (2) · France (2) · Italy (2) · Japan (1) · Spain (1) · United Kingdom (1)
John Mascarenhas, MD (2) · Amanda McBride, MD (1) · Andrew Roberts, MD (1) · Animesh Pardanani, MD (1) · Anthony M Hunter, MD (1) · Ayalew Tefferi, MD (1) · Jason Gotlib, MD (1) · Linda Wei, M.D. (1) · Lucia Masarova, MD (1) · Martha Wadleigh, MD (1) · Peter Abdelmessieh, DO, MSc (1) · Robert Morgan, MS, JD (1) · Ronald Hoffman, MD (1) · Ruben Mesa, MD (1)
PMID 27479177, PMID 29515114, PMID 38837732, PMID 40643151
P01CA108671 (2), 2019 (1), 2023 (1)